Sarah Houlton
Dr Sarah Houlton has a PhD in organic synthesis from Imperial College, and has been a science journalist specialising in chemistry-related topics since the early 1990s. Starting at the Journal of the Society of Dyers & Colourists, she then moved to the pharmaceutical industry magazine Manufacturing Chemist, ultimately becoming its editor. She has been freelance since 2001, and covers both science and business, with a particular interest in the pharma & biotech sector and the polyurethane industry, and the occasional foray into topics such as food ingredients and process engineering. She is based in Hertfordshire, UK.
BusinessUK government sets out antimicrobial resistance plan
Aims to cut antibiotic use and explore financial incentives for pharmaceutical companies
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
BusinessCancer immunotherapy spreads rapidly
New approvals and expanded use for checkpoint inhibitor drugs illustrate the power of Nobel-winning science
BusinessCleaning up clinical trials
Campaigns to enforce complete and correct reporting of trial data are beginning to take hold
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
BusinessGene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
BusinessRural power champion
Clementine Chambon is the 2018 Chemistry World Entrepreneur of the Year for her work using bioenergy to solve environmental, social and gender challenges in rural India
BusinessDeal protects world’s biggest selling drug from biosimilar erosion
AbbVie and Samsung Bioepis resolve patent litigation over arthritis drug Humira
BusinessAkzoNobel sells off specialty chemicals arm in €10bn deal
Private equity firm Carlyle sees off several other bidders
BusinessFit for repurpose
Drugs that can be used for new indications offer a potentially cheaper pathway – but only if the investors can recoup their costs
FeatureCarolyn Bertozzi
One-time heavy rocker Carolyn Bertozzi has made a name for herself with hit papers and sound science. Sarah Houlton charts her path to success
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
BusinessSanofi ordered to pull dengue vaccine
Philippines wants French drugmaker to cover immunisation program costs
NewsLiquid cats triumph at Ig Nobels
Papers on cats, vampire bats, digeridoos and cheese disgust all won at science’s most irreverent ceremony
SponsoredIn-house training speeds up metabolism
Business plugs DMPK skills gap to improve drug discovery
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
BusinessFDA asks Endo to take pain drug off market
Request part of larger strategy to address opioid misuse in the US
SponsoredSygnature Discovery
Sygnature Discovery is part of an innovative partnership to bolster the life science sector in Nottingham
FeatureAccess to drugs: a failure of pharma?
Many people around the world are either unable to afford the drugs they need, or their conditions have not been addressed by pharma R&D. Sarah Houlton investigates